Loading…
Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives
Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral saf...
Saved in:
Published in: | Journal of pharmaceutical sciences 1995-08, Vol.84 (8), p.927-932 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823 |
---|---|
cites | cdi_FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823 |
container_end_page | 932 |
container_issue | 8 |
container_start_page | 927 |
container_title | Journal of pharmaceutical sciences |
container_volume | 84 |
creator | Rajewski, Roger A. Traiger, George Bresnahan, James Jaberaboansar, Parinaz Stella, Valentino J. Thompson, Diane O. |
description | Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral safety of these derivatives was determined by survival of male mice after intraperitoneal (ip) injection, kidney histopathology, plasma urea nitrogen levels of mice determined 24h after injection, relativein vitrohemolytic potential and activated partial thromboplastin times (APTT). In addition, the 24-h renal excretion behavior of the derivatives was measured. Where appropriate, the results obtained with these cyclodextrin derivatives were compared with results obtained for β-CD and (hydroxypropyl)-β-cyclodextrin (HP-β-CD). The SAE-β-CD derivatives did not produce mortality in mice following ip injection at doses exceeding 5.45 mmol/kg. No significant histological lesions were observed in the kidney tissue of mice receiving the cyclodextrin derivatives. The SAE-β-CD derivatives were excreted faster and to a greater extent than β-CD and at rates comparable to HP-β-CD. The hemolytic potential of these derivatives was less than that of β-CD and comparable to or better than that of HP-β-CD. The SAE-β-CD derivatives did not increase APTT clotting times indicating that these derivatives have no significant anticoagulant activity. The toxicological profile of these derivatives suggests that these molecules may have application as biologically safe β-CD derivatives. |
doi_str_mv | 10.1002/jps.2600840805 |
format | article |
fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_jps_2600840805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915498594</els_id><sourcerecordid>ark_67375_WNG_2WLQKL6H_9</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823</originalsourceid><addsrcrecordid>eNqFkMFuEzEQhi0EKqFw5YbkA9cNtndt7x6rkLZABEEB9Wh57TG4dXYjexO6r8WD8Ey42iiIA-Jk2fP945kPoZeUzCkh7M3tLs2ZIKSuSE34IzSjnJFCECofo1kGWFHyqnmKnqV0SwgRhPMzdCZ5Lkk-Q9_WEYLf-k7HEW-0g2HEy4MOez34vsO9w2sdoRsg6hBGfGEz6lO-gsWbfXC9DndjwMvhO0T862exGE3oLdwP0Xf4LUR_yI0OkJ6jJ06HBC-O5zn6ern8srguVp-u3i0uVoWpuOCFzBOWtasNE1JaA9bld2I5p6KyIE0FLTBBa85dU3LKdduyqm2bVhvJWc3KczSf-prYpxTBqV3027ycokQ9CFNZmPojLAdeTYHdvt2CPeFHQ7n--ljXyejgou6MTyesFKykvM5YM2E_fIDxP5-q9-vNXyMUU_ZB7P0pq-OdErKUXN18vFLsZvX5w0pcqybz9cRDFnnwEFUyHrpsy0cwg7K9_9e2vwFyb6hg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives</title><source>Wiley-Blackwell Journals</source><creator>Rajewski, Roger A. ; Traiger, George ; Bresnahan, James ; Jaberaboansar, Parinaz ; Stella, Valentino J. ; Thompson, Diane O.</creator><creatorcontrib>Rajewski, Roger A. ; Traiger, George ; Bresnahan, James ; Jaberaboansar, Parinaz ; Stella, Valentino J. ; Thompson, Diane O.</creatorcontrib><description>Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral safety of these derivatives was determined by survival of male mice after intraperitoneal (ip) injection, kidney histopathology, plasma urea nitrogen levels of mice determined 24h after injection, relativein vitrohemolytic potential and activated partial thromboplastin times (APTT). In addition, the 24-h renal excretion behavior of the derivatives was measured. Where appropriate, the results obtained with these cyclodextrin derivatives were compared with results obtained for β-CD and (hydroxypropyl)-β-cyclodextrin (HP-β-CD). The SAE-β-CD derivatives did not produce mortality in mice following ip injection at doses exceeding 5.45 mmol/kg. No significant histological lesions were observed in the kidney tissue of mice receiving the cyclodextrin derivatives. The SAE-β-CD derivatives were excreted faster and to a greater extent than β-CD and at rates comparable to HP-β-CD. The hemolytic potential of these derivatives was less than that of β-CD and comparable to or better than that of HP-β-CD. The SAE-β-CD derivatives did not increase APTT clotting times indicating that these derivatives have no significant anticoagulant activity. The toxicological profile of these derivatives suggests that these molecules may have application as biologically safe β-CD derivatives.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.2600840805</identifier><identifier>PMID: 7500275</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>Washington: Elsevier Inc</publisher><subject>Animals ; Anticoagulants - toxicity ; Biological and medical sciences ; Blood Urea Nitrogen ; Chromatography, Thin Layer ; Cyclodextrins - administration & dosage ; Cyclodextrins - toxicity ; Cyclodextrins - urine ; Dextran Sulfate - toxicity ; Drug toxicity and drugs side effects treatment ; Erythrocytes - drug effects ; Excipients - administration & dosage ; Excipients - metabolism ; Excipients - toxicity ; Hemolysis - drug effects ; Humans ; In Vitro Techniques ; Injections, Intraperitoneal ; Kidney - pathology ; Male ; Medical sciences ; Mice ; Mice, Inbred Strains ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Partial Thromboplastin Time ; Pharmacology. Drug treatments</subject><ispartof>Journal of pharmaceutical sciences, 1995-08, Vol.84 (8), p.927-932</ispartof><rights>1995 Wiley-Liss, Inc., A Wiley Company</rights><rights>Copyright © 1995 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823</citedby><cites>FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.2600840805$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.2600840805$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3623158$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7500275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rajewski, Roger A.</creatorcontrib><creatorcontrib>Traiger, George</creatorcontrib><creatorcontrib>Bresnahan, James</creatorcontrib><creatorcontrib>Jaberaboansar, Parinaz</creatorcontrib><creatorcontrib>Stella, Valentino J.</creatorcontrib><creatorcontrib>Thompson, Diane O.</creatorcontrib><title>Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral safety of these derivatives was determined by survival of male mice after intraperitoneal (ip) injection, kidney histopathology, plasma urea nitrogen levels of mice determined 24h after injection, relativein vitrohemolytic potential and activated partial thromboplastin times (APTT). In addition, the 24-h renal excretion behavior of the derivatives was measured. Where appropriate, the results obtained with these cyclodextrin derivatives were compared with results obtained for β-CD and (hydroxypropyl)-β-cyclodextrin (HP-β-CD). The SAE-β-CD derivatives did not produce mortality in mice following ip injection at doses exceeding 5.45 mmol/kg. No significant histological lesions were observed in the kidney tissue of mice receiving the cyclodextrin derivatives. The SAE-β-CD derivatives were excreted faster and to a greater extent than β-CD and at rates comparable to HP-β-CD. The hemolytic potential of these derivatives was less than that of β-CD and comparable to or better than that of HP-β-CD. The SAE-β-CD derivatives did not increase APTT clotting times indicating that these derivatives have no significant anticoagulant activity. The toxicological profile of these derivatives suggests that these molecules may have application as biologically safe β-CD derivatives.</description><subject>Animals</subject><subject>Anticoagulants - toxicity</subject><subject>Biological and medical sciences</subject><subject>Blood Urea Nitrogen</subject><subject>Chromatography, Thin Layer</subject><subject>Cyclodextrins - administration & dosage</subject><subject>Cyclodextrins - toxicity</subject><subject>Cyclodextrins - urine</subject><subject>Dextran Sulfate - toxicity</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Erythrocytes - drug effects</subject><subject>Excipients - administration & dosage</subject><subject>Excipients - metabolism</subject><subject>Excipients - toxicity</subject><subject>Hemolysis - drug effects</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Injections, Intraperitoneal</subject><subject>Kidney - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Partial Thromboplastin Time</subject><subject>Pharmacology. Drug treatments</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNqFkMFuEzEQhi0EKqFw5YbkA9cNtndt7x6rkLZABEEB9Wh57TG4dXYjexO6r8WD8Ey42iiIA-Jk2fP945kPoZeUzCkh7M3tLs2ZIKSuSE34IzSjnJFCECofo1kGWFHyqnmKnqV0SwgRhPMzdCZ5Lkk-Q9_WEYLf-k7HEW-0g2HEy4MOez34vsO9w2sdoRsg6hBGfGEz6lO-gsWbfXC9DndjwMvhO0T862exGE3oLdwP0Xf4LUR_yI0OkJ6jJ06HBC-O5zn6ern8srguVp-u3i0uVoWpuOCFzBOWtasNE1JaA9bld2I5p6KyIE0FLTBBa85dU3LKdduyqm2bVhvJWc3KczSf-prYpxTBqV3027ycokQ9CFNZmPojLAdeTYHdvt2CPeFHQ7n--ljXyejgou6MTyesFKykvM5YM2E_fIDxP5-q9-vNXyMUU_ZB7P0pq-OdErKUXN18vFLsZvX5w0pcqybz9cRDFnnwEFUyHrpsy0cwg7K9_9e2vwFyb6hg</recordid><startdate>199508</startdate><enddate>199508</enddate><creator>Rajewski, Roger A.</creator><creator>Traiger, George</creator><creator>Bresnahan, James</creator><creator>Jaberaboansar, Parinaz</creator><creator>Stella, Valentino J.</creator><creator>Thompson, Diane O.</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>American Pharmaceutical Association</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199508</creationdate><title>Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives</title><author>Rajewski, Roger A. ; Traiger, George ; Bresnahan, James ; Jaberaboansar, Parinaz ; Stella, Valentino J. ; Thompson, Diane O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Animals</topic><topic>Anticoagulants - toxicity</topic><topic>Biological and medical sciences</topic><topic>Blood Urea Nitrogen</topic><topic>Chromatography, Thin Layer</topic><topic>Cyclodextrins - administration & dosage</topic><topic>Cyclodextrins - toxicity</topic><topic>Cyclodextrins - urine</topic><topic>Dextran Sulfate - toxicity</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Erythrocytes - drug effects</topic><topic>Excipients - administration & dosage</topic><topic>Excipients - metabolism</topic><topic>Excipients - toxicity</topic><topic>Hemolysis - drug effects</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Injections, Intraperitoneal</topic><topic>Kidney - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Partial Thromboplastin Time</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rajewski, Roger A.</creatorcontrib><creatorcontrib>Traiger, George</creatorcontrib><creatorcontrib>Bresnahan, James</creatorcontrib><creatorcontrib>Jaberaboansar, Parinaz</creatorcontrib><creatorcontrib>Stella, Valentino J.</creatorcontrib><creatorcontrib>Thompson, Diane O.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rajewski, Roger A.</au><au>Traiger, George</au><au>Bresnahan, James</au><au>Jaberaboansar, Parinaz</au><au>Stella, Valentino J.</au><au>Thompson, Diane O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>1995-08</date><risdate>1995</risdate><volume>84</volume><issue>8</issue><spage>927</spage><epage>932</epage><pages>927-932</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral safety of these derivatives was determined by survival of male mice after intraperitoneal (ip) injection, kidney histopathology, plasma urea nitrogen levels of mice determined 24h after injection, relativein vitrohemolytic potential and activated partial thromboplastin times (APTT). In addition, the 24-h renal excretion behavior of the derivatives was measured. Where appropriate, the results obtained with these cyclodextrin derivatives were compared with results obtained for β-CD and (hydroxypropyl)-β-cyclodextrin (HP-β-CD). The SAE-β-CD derivatives did not produce mortality in mice following ip injection at doses exceeding 5.45 mmol/kg. No significant histological lesions were observed in the kidney tissue of mice receiving the cyclodextrin derivatives. The SAE-β-CD derivatives were excreted faster and to a greater extent than β-CD and at rates comparable to HP-β-CD. The hemolytic potential of these derivatives was less than that of β-CD and comparable to or better than that of HP-β-CD. The SAE-β-CD derivatives did not increase APTT clotting times indicating that these derivatives have no significant anticoagulant activity. The toxicological profile of these derivatives suggests that these molecules may have application as biologically safe β-CD derivatives.</abstract><cop>Washington</cop><pub>Elsevier Inc</pub><pmid>7500275</pmid><doi>10.1002/jps.2600840805</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3549 |
ispartof | Journal of pharmaceutical sciences, 1995-08, Vol.84 (8), p.927-932 |
issn | 0022-3549 1520-6017 |
language | eng |
recordid | cdi_crossref_primary_10_1002_jps_2600840805 |
source | Wiley-Blackwell Journals |
subjects | Animals Anticoagulants - toxicity Biological and medical sciences Blood Urea Nitrogen Chromatography, Thin Layer Cyclodextrins - administration & dosage Cyclodextrins - toxicity Cyclodextrins - urine Dextran Sulfate - toxicity Drug toxicity and drugs side effects treatment Erythrocytes - drug effects Excipients - administration & dosage Excipients - metabolism Excipients - toxicity Hemolysis - drug effects Humans In Vitro Techniques Injections, Intraperitoneal Kidney - pathology Male Medical sciences Mice Mice, Inbred Strains Miscellaneous (drug allergy, mutagens, teratogens...) Partial Thromboplastin Time Pharmacology. Drug treatments |
title | Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T01%3A02%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preliminary%20Safety%20Evaluation%20of%20Parenterally%20Administered%20Sulfoalkyl%20Ether%20%CE%B2-Cyclodextrin%20Derivatives&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Rajewski,%20Roger%20A.&rft.date=1995-08&rft.volume=84&rft.issue=8&rft.spage=927&rft.epage=932&rft.pages=927-932&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.2600840805&rft_dat=%3Cistex_cross%3Eark_67375_WNG_2WLQKL6H_9%3C/istex_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/7500275&rfr_iscdi=true |